Immunohistochemical analysis is the gold standard method to assess the programmed death-ligand 1 protein (PD-L1) expression status in patients affected by non-small cell lung cancer (NSCLC) to guide immunotherapy. Here, CD274 is linked to non-small cell lung carcinoma.